References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2015-5-28-33

medsovet-169

Research Article

КОГНИТИВНЫЕ НАРУШЕНИЯ И ДЕМЕНЦИЯ

COGNITIVE IMPAIRMENT AND DEMENTIA

Ранняя диагностика и лечение болезни Альцгеймера

Early diagnosis and treatment of Alzheimer's disease

Парфенов

В. А.

Parfyonov

V. A.

noemail@neicon.ru

Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияthe First Moscow State Medical University named after I.M. SechenovRussian Federation

2015

30122015

052833

2015

Парфенов В.А.

Parfyonov V.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/169

Представлен обзор литературных данных по ранней диагностике и лечению болезни Альцгеймера (БА). Обсуждаются лекарственные и нелекарственные методы лечения БА. Отмечается эффективность психосоциальных и поведенческих методов терапии, когнитивного тренинга у пациентов с БА. Изложены данные об эффективности ингибиторов центральной ацетилхолинэстеразы (донепезил, галантамин, ривастигмин) и мемантина в улучшении когнитивных функций, поведения и ежедневной активности пациентов с БА. Отмечаются эффективность донепезила (Алзепил) на разных стадиях заболевания у пациентов с БА и целесообразность его использования в дозе 10 мг/сут для получения максимально возможного положительного эффекта. Ранняя диагностика и эффективное лечение пациентов с БА могут существенно улучшить качество жизни не только пациентов, но и их ближайшего окружения.

There is an overview of literature devoted to the early diagnosis and treatment of Alzheimer's disease (AD). Medication and non-medication treatment methods for AD are discussed. The efficacy of psychosocial and behavioral therapies and cognitive training for patients with AD is highlighted. The efficacy of central acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine in improving cognitive function, behavior and activities of daily living in oatient with AD is highlighted. The article tells about the efficacy of donepezil (Alzepil) at different stages of the disease in patients with AD and rationality of its use at 10 mg daily to achieve the best possible effect. Early diagnosis and effective treatment of patients with AD could significantly enhance the quality of life not only for patients but also for their closest relations.

болезнь Альцгеймераингибиторы центральной ацетилхолинэстеразыдонепезилгалантаминривастигминмемантинAlzheimer's diseasecentral acetylcholinesterase inhibitorsdonepezilgalantaminerivastigminememantine

References1

Hendrie H.C. Epidemiology of dementia and Alzheimer's disease. J Am Psych., 1998,.6: 3-18.

Alzheimer's Disease International. World Alzheimer Report 2010: The global economic impact of dementia. Alzheimer's Disease International website. //www.alz.co.uk/research/ files/WorldAlzheimerReport2010.pdf. Accessed May 10, 2012.

Гаврилова С.И. Болезнь Альцгеймера: современные представления и диагностике и терапии. М., 2012.

Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014.

Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising of the NINCDS-ADRDRA criteria. Lancet Neurol., 2007, 6: 734-746.

Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep. 2010, 12: 20-27,

Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012.

Aisen PS, Cummings J, Schneider LS. Symptomatic and Nonamyloid.Tau Based Pharmacologic Treatment for Alzheimer Disease. Cold Spring Harb Perspect Med 2012, 2: a006395.

Panza F, Solfrizzi V, Frisardi V et al. Disease modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators [review]. Drugs Aging. 2009, 26: 537-555.

Salomone S, Caraci F, Leggio GM et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2011, 73: 504-517.

Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006, 1: CD005593.

Hansen RA, Gartlehner G, Webb AP et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin IntervAging, 2008, 3: 211225.

Meguro K, Ouchi Y, Akanuma K et al. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities. BMC Neurology 2014, 14: 243.

Hansen RA, Gartlehner G, Webb AP. Efficacy and safety of donepezil, galantamine, and rivastig-mine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008, 3: 211-225.

Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005, 59: 817-822.

Карпюк В.А, Дудук С.Л., Лелявко И.А. и др. Изучение эффективности и безопасности Алзепила (донепезила) на стадии мягкой и умеренно выраженной деменции. Современная терапия в психиатрии и неврологии 2012, 3: 27-31.

Nakamura K, Watanabe N, Ohkawa H et al. Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer's disease. Patient Preference and Adherence 2014, 8: 1223-1228.

Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341.

van Dyck CH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry. 2006, 14: 428-437.

Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2009, 27: 164-172.

Schneider LS, Dagerman KS, Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005, 294: 1934-1943.

Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol 2009, 8: 151-157.

Weintraub D, Rosenberg PB, Drye LT et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry, 2010, 18: 332-340.

Парфенов В.А., Неверовский Д.В. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия и психосоматика, 2015, 1: 37-42.

The authors declare that there are no conflicts of interest present.